Aspire Biopharma Warrant
ASBPW
27 hedge funds and large institutions have $145K invested in Aspire Biopharma Warrant in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
0.43% less ownership
Funds ownership: 27.71% → 27.28% (-0.43%)
3% less capital invested
Capital invested by funds: $151K → $145K (-$5.08K)
7% less funds holding
Funds holding: 29 → 27 (-2)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$739 |
| 2 |
FTUS
Flow Traders U.S.
New York
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAS
VR Advisory Services
Camana Bay, Grand Cayman,
Cayman Islands
|
-$1.66K |
| 2 |
AC
Athos Capital
Hong Kong
|
-$1K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$279 |
| 4 |
Barclays
London,
United Kingdom
|
-$151 |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$2 |
ASBPW Hedge Fund Activity: Q2 2026 in Review
27 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q2 2026, worth a combined $145K — down 3.4% from $151K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ASBPW and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $739. The largest seller was VR Advisory Services, exiting entirely with an estimated $1.66K sold.
- 27 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q2 2026, down from 29 in Q1 2026.
- Funds reported $145K of Aspire Biopharma Warrant stock for Q2 2026, down 3.4% quarter-over-quarter.
- 1 fund opened new Aspire Biopharma Warrant positions in Q2 2026 and 3 closed out, a net change of -2 holders.
- The largest Aspire Biopharma Warrant buyer in Q2 2026 was Two Sigma Securities, an estimated $739 added.
- The largest Aspire Biopharma Warrant seller in Q2 2026 was VR Advisory Services, an estimated $1.66K sold.
Based on aggregated 13F filings for Q2 2026.